Biocentury.com

Bio Century. Managers, investors, scientists and regulators to manage the translation of science into medicine.

Today's Biocentury.com headlines: Observe fresh posts and updates on Bio Century. It is pretty active and updates frequently with 100+ articles published this month alone (they might potentially reach about 4.6K visitors within the said period of time). It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Bio Century

Subscribe to related news

Sanofi left looking after J&J swipes Actelion in $30B deal
via thedealnewsroom.tumblr

The French drug maker’s CEO Olivier Brandicourt once more showcased his deal discipline, but he could also do without pesky Americans snapping up his targets. By Paul Whitfield Sanofi SA’ CEO Olivier Brandicourt must be tiring of losing biotech targets...
Johnson & Johnson agrees to acquire biotech company Actelion for $30bn
via europeanceo

Johnson & Johnson CEO Alex Gorsky will be sitting pretty as head of an even larger firm once the deal goes through On January 26, Johnson & Johnson, the world’s largest healthcare company, announced it will acquire Swiss pharmaceuticals and...
Johnson & Johnson to acquire all of the outstanding shares of Actelion for $280 per share payable in U.S. dollars
via news.europawire

In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be...
Johnson & Johnson to make takeover approach for drugmaker Actelion
via businessfortnight

London/New York: The Johnson & Johnson has approached Actelion Ltd about a potential takeover of the $17 billion Swiss drugmaker as the US health-care giant works to expand its pharmaceutical lineup, people familiar with the matter said. Deliberations...
Johnson & Johnson to Acquire Actelion for $30 Billion
via diversityinc

Johnson & Johnson (No. 8 on the DiversityInc Top 50 Companies list) and Actelion Ltd. announced January 26 that they have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland...

Biocentury.com popular pages

BioCentury - Home

Essential business intelligence for biopharma executives, managers, investors, scientists and regulators to manage the translation of science into medicine.
Keytruda, pembrolizumab (MK-3475, lambrolizumab) - BioCentury Product Profiles - BCIQ

Keytruda, pembrolizumab (MK-3475, lambrolizumab) - BioCentury Product Profiles for the biopharma industry